These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 9657437

  • 1. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.
    Pislaru SV, Pislaru C, Zhu X, Arnout J, Stassen T, Vanhove P, Herbert JM, Meuleman DG, Van de Werf F.
    Thromb Haemost; 1998 Jun; 79(6):1130-5. PubMed ID: 9657437
    [Abstract] [Full Text] [Related]

  • 2. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L, Arnout J, Vanhove P, Dol F, Lormeau JC, Herbert JM, Collen D, Van de Werf F.
    Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
    [Abstract] [Full Text] [Related]

  • 3. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 4. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 5. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 6. In vivo effects of contrast media on coronary thrombolysis.
    Pislaru S, Pislaru C, Szilard M, Arnout J, Van de Werf F.
    J Am Coll Cardiol; 1998 Oct; 32(4):1102-8. PubMed ID: 9768739
    [Abstract] [Full Text] [Related]

  • 7. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 8. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
    [Abstract] [Full Text] [Related]

  • 9. Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.
    Stassen JM, Rapold HJ, Vanlinthout I, Collen D.
    Thromb Haemost; 1993 May 03; 69(5):454-9. PubMed ID: 8391726
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS, Bentley RG, Morgan SR, Kasiewski CJ, Chu V, Perrone MH, Leadley RJ.
    Br J Pharmacol; 2001 Aug 03; 133(7):1190-8. PubMed ID: 11487531
    [Abstract] [Full Text] [Related]

  • 11. Selective venous thrombolysis with the nipple-balloon catheter: comparative evaluation in vivo.
    Roy S, Laerum F, Brosstad F, Kvernebo K, Sakariassen KS.
    J Vasc Interv Radiol; 1999 Jun 03; 10(6):817-24. PubMed ID: 10392954
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty.
    Vuillemenot A, Schiele F, Meneveau N, Claudel S, Donat F, Fontecave S, Cariou R, Samama MM, Bassand JP.
    Thromb Haemost; 1999 Feb 03; 81(2):214-20. PubMed ID: 10063994
    [Abstract] [Full Text] [Related]

  • 13. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
    Vanderschueren S, Collen D.
    Thromb Haemost; 1996 May 03; 75(5):816-9. PubMed ID: 8725729
    [Abstract] [Full Text] [Related]

  • 14. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
    Susawa T, Yui Y, Hattori R, Takahashi M, Aoyama T, Takatsu Y, Sakaguchi K, Yui N, Kawai C.
    Jpn Circ J; 1987 Apr 03; 51(4):431-5. PubMed ID: 2441082
    [Abstract] [Full Text] [Related]

  • 15. Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
    Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, Willerson JT.
    Trans Assoc Am Physicians; 1993 Apr 03; 106():110-9. PubMed ID: 8036734
    [No Abstract] [Full Text] [Related]

  • 16. Reocclusion after thrombolysis: a problem solved by hirudin?
    Rübsamen K, Eschenfelder V.
    Blood Coagul Fibrinolysis; 1991 Feb 03; 2(1):97-100. PubMed ID: 1773004
    [Abstract] [Full Text] [Related]

  • 17. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Nordt TK, Moser M, Kohler B, Ruef J, Peter K, Kübler W, Bode C.
    Thromb Haemost; 1998 Dec 03; 80(6):881-6. PubMed ID: 9869154
    [Abstract] [Full Text] [Related]

  • 18. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A, Casilli F, Assanelli E, Grazi M, Marenzi G, Guazzi MD.
    Thromb Haemost; 2001 Oct 03; 86(4):991-4. PubMed ID: 11686357
    [Abstract] [Full Text] [Related]

  • 19. Selective thrombolysis in acute deep vein thrombosis: evaluation of adjuvant therapy in vivo.
    Roy S, Brosstad F, Sakariassen KS.
    Cardiovasc Intervent Radiol; 1999 Oct 03; 22(5):403-10. PubMed ID: 10501893
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
    Peters RJ, Spickler W, Théroux P, White H, Gibson M, Molhoek PG, Anderson HV, Weitz JI, Hirsh J, Weaver WD.
    Am Heart J; 2001 Aug 03; 142(2):237-43. PubMed ID: 11479461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.